Risk of Nephrogenic Systemic Fibrosis in Patients With Stage ... | 化學工廠資訊網
由SAWoolen著作·2020·被引用126次—...inpatientswithstage4or5chronickidneydiseasereceiving....symptomsfollowing22,897gadotericacid(Dotarem®)examinations, ...
Key PointsQuestion What is the risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent?
Findings In this systematic review and meta-analysis of 16 unique studies and 4931 patients, the pooled incidence of nephrogenic systemic fibrosis after administration of a group II gadolinium-based contrast agent in patients with stage 4 or 5 chronic kidney disease was 0%; the upper bound of the 95% CI was 0.07%.
Meaning Findings suggest that the risk of nephrogenic systemic fibrosis from group II gadolinium-based contrast agent administration in stage 4 or 5 chronic kidney disease is likely less than 0.07%; potential diagnostic harms of withholding group II gadolinium-based contrast agents for indicated examinations may outweigh the risk of nephrogenic systemic fibrosis in this pop...
Dotarem (bottles and pre | 化學工廠資訊網
DOTAREM (gadoterate meglumine) Injection for intravenous use | 化學工廠資訊網
Gadolinium | 化學工廠資訊網
Nephrogenic systemic fibrosisnephrogenic fibrosing ... | 化學工廠資訊網
Pharmacokinetics and tolerance of Gd | 化學工廠資訊網
Renal Safety Evaluation After Dotarem® | 化學工廠資訊網
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage ... | 化學工廠資訊網
Use of Intravenous Gadolinium | 化學工廠資訊網
【新北市】七星化學製藥股份有限公司
新北市化工廠有哪些?本篇為大家整理位於土城區福安街75號的「七星化學製藥股份有限公司」相關資訊,用列表的方式整理給大家...